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Abstract
Context: Identifying patients at risk for adverse outcomes of Clostridium difficile infection (CDI), including recurrence and
death, will become increasingly important as novel therapies emerge, which are more effective than traditional approaches
but very expensive. Clinical prediction rules (CPRs) can improve the accuracy of medical decision-making. Several CPRs have
been developed for CDI, but none has gained a widespread acceptance.
Methods: We systematically reviewed studies describing the derivation or validation of CPRs for unfavourable outcomes of
CDI, in medical databases (Medline, Embase, PubMed, Web of Science and Cochrane) and abstracts of conferences.
Results: Of 2945 titles and abstracts screened, 13 studies on the derivation of a CPR were identified: two on
recurrences, five on complications (including mortality), five on mortality alone and one on response to treatment.
Two studies on the validation of different severity indices were also retrieved. Most CPRs were developed as secondary
analyses using cohorts assembled for other purposes. CPRs presented several methodological limitations that could
explain their limited use in clinical practice. Except for leukocytosis, albumin and age, there was much heterogeneity in
the variables used, and most studies were limited by small sample sizes. Eight models used a retrospective design.
Only four studies reported the incidence of the outcome of interest, even if this is essential to evaluate the potential
usefulness of a model in other populations. Only five studies performed multivariate analyses to adjust for
confounders.
Conclusions: The lack of weighing variables, of validation, calibration and measures of reproducibility, the weak validities
and performances when assessed, and the absence of sensitivity analyses, all led to suboptimal quality and debatable utility
of those CPRs. Evidence-based tools developed through appropriate prospective cohorts would be more valuable for
clinicians than empirically-developed CPRs.
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Introduction
In the decade that followed the emergence of the Clostridium
difficile hypervirulent strain NAP1/BI/027 in North America and
Western Europe, health professionals have been increasingly
challenged by the burden of this infection, its frequent recurrences,
severe complications and deaths [1–4].
Currently, the management of severe, complicated Clostridium
difficile infection (CDI) is based on high-dose vancomycin, with or
without intravenous metronidazole, intensive care unit (ICU)
admission, vasopressor support and colectomy for a few selected
patients [5,6]. Most patients present initially with similar
symptoms, and identifying which ones might progress to these
dreadful complications is difficult.
After a long period of stagnation, novel therapeutic approaches
are being developed for CDI. Fidaxomicin, recently licensed by
the Food and Drug Administration, is more effective than
vancomycin in avoiding recurrences [7,8]. Monoclonal antibodies
were also proven to be effective in preventing recurrences, in a
phase 2 trial [9]. Both fidaxomicin and monoclonal antibodies are
unfortunately very expensive. Thus, it will become increasingly
important to identify, early in the course of the disease, which
patients would be most likely to benefit from these novel therapies,
from closer follow-up, or both [10], ultimately to decrease CDI-
related morbidity and mortality.
Clinical prediction rules (CPRs), which can improve the accuracy
of medical decision-making, could address some of the aforemen-
tioned challenges in CDI management, and facilitate the conduct of
clinical trials evaluating experimental therapeutic approaches.
Several CPRs for CDI complications have been proposed over
the years, but none has gained widespread clinical acceptance. We
therefore performed a systematic review of all publications that
aimed to derive or validate a CPR to predict recurrences,
complications and mortality in patients diagnosed with CDI.
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Study selection
A systematic review was performed according to PRISMA
guidelines [11] (checklist S1) using an electronic search (Text
S1) of all studies published since January 1978 (the year that C.
difficile was identified as the etiological agent of pseudomembra-
nous colitis [12,13]), in English, French or Spanish. The search
was limited to humans and used the following online libraries and
databases: Medline, PubMed, Cochrane, Embase and Web of
Science. Furthermore, we reviewed abstracts submitted to
conferences organised by the American Society for Microbiology,
the Society for Healthcare Epidemiology of America, the
Infectious Diseases Society of America, the Association of
Medical Microbiology and Infectious Disease Canada, the
Anaerobe Society of the Americas and the European Society of
Clinical Microbiology and Infectious Diseases. In addition, the
reference lists of identified CPRs were searched manually (cross-
referencing). The final electronic search was performed on 30
October 2011.
Inclusion criteria
Publications from all sources were gathered in one file and
duplicates were removed. A first screening of titles and abstracts
followed by a full-text review were performed by CAC in order to
identify studies that: i) focused on C. difficile as the main pathogen;
ii) measured at least one relevant outcome: severity of the
infection, complications, mortality, treatment failures or recur-
rences; and iii) developed or validated a model or risk score, a
prediction rule, an index or a scale. Quality control on 10% of
electronic search results was performed (LV) for the first screening
of abstracts, as well as for all included studies. Reviewers had a
good agreement concerning eligible studies (87%). Disagreements
were resolved by a third party (JP).
Data collection
The following data were extracted by two reviewers (CAC and
LV), from each included publication, into a standardized matrix:
definitions of main outcomes, description of the study design, study
population, sample size, statistical analyses and main results in
relation with the objectives of the review. Authors were directly
contacted in case of missing or incomplete data.
Quality assessment
The quality of CPR derivation studies in full-text publications
was assessed qualitatively through a description of biases and
limitations, and quantitatively through the attribution of points for
the derivation and validation methodologies. The criteria of
Laupacis [14], McGinn [15], and May [16] were used as standards
for the essential steps in the derivation, validation and reporting of
CPRs. A total of 20 points could be reached for the derivation
methodology and of 10 for the validation, with one point assigned
to each step (Text S2). The impacts of the CPRs (potential effects
if implemented into practice) and the subsequent work to
determine their accuracy were considered optional in the
publications on the derivation of a CPR and were not included
in the quality assessment.
Results
Search results
The electronic search led to 7111 publications. After excluding
duplicates, 2945 (41%) were reviewed by title and abstract
(Figure 1). According to pre-defined criteria, 2754 (94%)
publications were excluded. Following the full-text review, we
retained 15 studies: 13 studies on the derivation of prediction rules
or models, including or not a validation process, and two studies
on validation alone. Overall, we identified two derivation studies
on recurrences, five on complications/severity including mortality,
Figure 1. Flow chart of publications’ inclusion and exclusion.
doi:10.1371/journal.pone.0030258.g001
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validation studies focused on severity indices.
I. Derivation studies
As shown in Figures 2–4, leukocytosis (white cell count, [WCC])
was included in the majority of the scores (n=9) and hypo-
albuminemia in half of them (n=6). In studies with univariate
analyses, prediction models were based on long lists of criteria
(between 4 and 13). Few criteria remained significant after
multivariate analyses, with older age being the most frequent
(n=5). All but one [17] studies on complications included only
univariate associations. In addition, we included Miller’s study
(Correlation of the ATLAS bedside scoring system and its
components with cure and recurrence of C. difficile infection.
IDSA Annual Meeting, 2009) on predicting recurrence 28 days
after end of therapy (Figure 4). The score correlated with cure
much better than with recurrence (R
2=0.85 vs. 0.32), and
correlated with recurrence only among patients receiving
fidaxomicin (R
2=0.7 vs. 0.02 for those given vancomycin). This
score was used to predict mortality in a second cohort (n=308;
mortality=8%) by comparing the median score in survivors and
non-survivors: the difference was significant (p=0.0002). (Chopra
et al. ATLAS-A bedside scoring system predicting mortality due to
C. difficile infection in elderly hospitalized patients. IDSA Annual
Meeting, 2010).
Study data and quality assessment
Overall, only four studies reported the incidence of the outcome
of interest [18–21], eight used a retrospective design for derivation
and six used multivariate analysis. Prospective collection of
outcomes was performed in only one study [19] and blinding to
assess outcomes in two studies [18,19]. Assigning points to each
variable in the scores proportionally to the variables’ coefficients
was performed in only four studies [17,18,22,23]. Therefore, only
four studies obtained more than 10/20 points with regard to the
quality of derivation methodology (Table 1).
Furthermore, only two studies used a validation cohort [17,22].
A total of 8/10 points was assigned to Hu’s [22] and of two to
Zilberberg’s studies [18]. Seven studies reported validation and
performance parameters of scores or models (Table 2). To our
knowledge, Rubin [24] did not validate their scoring system, but it
was later validated by Fujitani [25]. Welfare [23] assessed the
internal validity of their score through a Chi-square comparison
between the two halves of a split derivation cohort. [21,26].
Other limitations were identified. Hu [22] used risk factors that
had been associated with recurrence in a previous study [27].
Velazquez-Gomez [21], Drew [28] and Belmares [20] empirically
derived a scoring system using laboratory data and factors
previously associated with severe disease, refractoriness to
treatment and mortality. The severity of disease in the study of
Velazquez-Gomez [21] was defined a priori according to the
Figure 2. Prediction scores for complications of CDI.
doi:10.1371/journal.pone.0030258.g002
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doi:10.1371/journal.pone.0030258.g003
Figure 4. Prediction scores of recurrence of CDI and treatment success.
doi:10.1371/journal.pone.0030258.g004
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patients fulfilling more than seven criteria, including hypotension,
tachycardia and ICU admission. Older age was one of the
variables in Zilberberg’s score [18] initially derived to predict
mortality among the elderly (Figure 3), but the weight given to age
was potentially over-estimated by being also included within the
APACHE II score [29]. The ARC score (age, renal disease and
cancer) [23] was initially based on age and co-morbidities, but.
ORs were rounded down and significative variables with OR
between 1 and 1.5 were left out. Miller used participants in a
clinical trial to develop their prediction score (Figure 4). Clinical
trials are carried out with restrictive inclusion criteria, which
somewhat limits the external validity of this score if used in the
general population of patients with CDI.
Performance measures
Frequencies of observed or predicted outcomes of interest by the
CPRs were low across studies, ranging between 15% and 66%. In
Na’s study [17], the maximum possible score (n=7) was
equivalent to only 36% of the risk of severity, including death.
In Lungulescu’s study [30], 29% of severe cases had a score $2
among four possible criteria. On the other hand, with only two
clinical parameters (WCC and BUN), Im [31] predicted 50% of
the risk of mortality, and with .2 among 7 criteria Belmares [20]
predicted only 67% of treatment failures.
When reported, sensitivities (38%–82%), specificities (62%–
93%), positive predictive values (PPV; 25%–50%) and diagnostic
accuracy (69%–72%) were relatively low (Table 2). The area-
under-the-curve (AUC) values were modest; the highest (0.9;
IC95%=0.8–1.0) corresponded to a score of 2.5 over 7 in
Belmares’ cross-validation [20] although few patients experienced
true treatment failures (Figure 4). None of the included studies
reported analysis of likelihood ratios, sensitivity analyses, the
potential effects if the CPRs were implemented into practice, nor a
follow-up to determine accuracy in real-life use.
II. Validation studies
The score of Velazquez-Gomez [21] (severity score index) was
prospectively validated by Toro [26]. A cohort of CDI patients
(male veterans; n=54) with a score corresponding to mild,
moderate and severe disease at diagnosis (Figure 2) was followed
for 90 days to assess the severity and mortality. The validity of the
score was assessed through Chi-square comparisons. Need of ICU
care and mortality correlated with high severity in the index
(p,0.05 and p=0.005 respectively). In quality assessment, this
study was assigned 2 points over 10.
Fujitani [25] analysed eight severity score indices, most of them
with no published data concerning their derivation and validation.
They were rather validated in a prospective cohort (n=184) using
the Center for Disease Control and Prevention definition of
Table 1. Assessment of quality of CPRs in the derivation process.
Study (1
st author)
Lungulesco
[30] Hu [22]
Zilberberg
[18]
Bhangu
[19]
Belmares
[20]
Welfare
[23]
Drew
[28]
Velazquez-Gomez
[21]
Rubin
[24]
A. Clearly defined outcomes !! !! ! ! ! - !
B. Prospective predictors -- -! -- - - -
C. Description of subjects
Inclusion criteria !! !! ! ! - !!
Method of selection !! !! ! ! - !!
Demographic characteristics !! !! ! -- !!
Clinical characteristics !! -
D. Sample size
a ! - !! - ! -- -
E. Comparison group ! - !! ! -- ! -
F. Univariate analysis
b ! - !! -- - !!
G. Multivariate analysis - !! ! - ! -- -
H. Accuracy
Sensitivity !! -- ! - ! --
Specificity !! -- ! - ! --
PPV !! -- - - ! --
NPV !! -- - - ! --
Likelihood ratios - - - - - - - - -
AUC !! !- ! -- - -
Confidence intervals - !! - ! - ! --
I. Blinding in assessing
outcomes
-- !! -- - - -
J. Scores proportional to b
c - !! ! - ! -- -
Total quality score 13 13 12 11 9 6 6 5 5
aSample size: at least 10 outcomes per predictor variable;
bUnivariate analysis of predictors;
cb coefficient: estimate in multivariate logistic regression.
doi:10.1371/journal.pone.0030258.t001
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ICU, surgery for toxic megacolon, bowel perforation, refractory
colitis, or 30- day death attributed to CDI [6]. Indices had
moderate sensitivities (63–84%), low PPV (19–57%), and poor
concordance with CDC definitions (Kappa score: 0.18 to 0.69).
Apart from the scores of Rubin [24] and Belmares [20] included in
our review, the other indices were mainly used for definition of
CDI severity at diagnosis and were not derived for prediction [32–
35]. None of those indices assessed a risk of an unfavourable
outcome.
Discussion
To our knowledge, this is the first systematic review of
prediction tools for unfavourable outcomes of CDI, offering to
practitioners a comprehensive summary and assessment of
available CPRs. Standard methodology for systematic reviews
was followed with rigorous quality control. Numerous key words
and medical databases were used, and a very large number of
publications were scanned in order to retrieve all available CPRs
of interest. Furthermore, in order to identify CPRs in grey
literature: conference abstracts of six major infectious diseases
societies were searched.
Most CPRs on unfavourable outcomes of CDI were developed
as secondary analyses using cohorts assembled for other purposes.
CPRs included in the current systematic review presented several
methodological limitations that could explain their very limited use
in clinical practice. Except for WCC, albumin and age, there was
much heterogeneity in the variables used in various scores, and
most studies were limited by small sample sizes. Eight of the
included models used a retrospective design, and one used the
population of a clinical trial. It is generally suggested that
predictive variables should be collected prospectively, and
therefore more accurately, in a process established specifically
for the development and the validation of clinical rules [14,16].
Only four studies reported the incidence of the outcome of
interest, even if this information is essential to evaluate the
potential usefulness of a given model in populations other than the
one used for its derivation [36]. In addition, analysis of likelihood
ratios in the validation process is independent from the incidence
of the outcome [37] but none of the included studies reported any
such measures. Multivariate analyses are also recommended for
the derivation process in order to account for the confounding and
interaction between variables [14]. Only five studies performed
multivariate analyses, but their results need to be interpreted
cautiously since the confidence intervals for the adjusted odds
ratios were wide.
The majority of CPRs were developed to predict the likelihood
of complications or severe CDI, including death. Only two CPR
were published on recurrences, one from a small retrospective
cohort and the other from a clinical trial with a restricted
population. Recurrence is an important problem associated with
CDI, causing significant morbidity [38,39]. The availability of
costly new treatments potentially lowering the rate of recurrence
Table 2. Reported validation and performance parameters of prediction scores or models (95% confidence interval).
Study Model Sensitivity Specificity PPV
1 NPV
¢ AUC
£
Diagnostic
accuracy
Derivation step
Lungulescu [30]: Cut-off
score: 2 of 4 criteria
History of malignancy + WBC $20610
9/L
+ albumin ,3?0 mg/dL + creatinine
.1?56baseline
82% 65% 38% 93% 0.8 69%
Drew [28]: Cut-off
score $4
Lab results on day1 (Ration WCC,
WCC, urea and albumin)
80% (39–96) 77% (74–79) 25% (12–30) 98% (93–100) - -
Lab results on day3 63% (32–86) 82% (79–85) 29% (15–40) 95% (91–98) - -
Lab results on day 1+ day 3 100% (59–100) 70% (66–70) - - - -
Im [31]: 2-variables model WBC $30610
9/L + BUN $4 0 m g / d L - ---0 . 9 -
Low risk (score=0) vs. high (score $1) 100% 62% - - - -
Model + moderate and severe
pericolonic stranding
100% 82% - - 0.9 -
Belmares [20] Optimal score=2.5 67% 93% - - 0.9
(0.8–1.0)
-
Validation step
Belmares score
in Fujitani [25]
Variables in the score against CDC
definition of severity
74% 93% 70% 97% - -
Hu [22] Age + Horn’s index + additional
antibiotics
54% (25–81) 77% (63–87) 37% (16–62) 87% (73–95) 0?8
(0?7–0?9)
72%
(59–82)
Age + Horn’s index + additional
antibiotics + IgG
38% (9–76) 83% (59–96) 50% (12–88) 75% (51–91) 0?6
(0?4–0?8)
69%
(48–86)
Zilberberg [18]; Cross-
validation: bootstrap;
10% of sample; 25 iterations
Age $75 y + septic shock + no r
espiratory disease + Apache
II score $20
- ---0 ?7
(0?7-0?8)
-
Rubin [24] in Fujitani [25] Variables in the score against
CDC definition of severity
63% 87% 36% 95% - -
1PPV: positive predictive value;
¢NPV: negative predictive value;
£AUC: area under the ROC curve.
doi:10.1371/journal.pone.0030258.t002
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diagnosis patients at high risk of recurrence. None of the current
recurrence scores seems to be able to predict recurrence with
accuracy. The development and validation of recurrence scores
should be a priority.
We designed a scale to assess the quality of methodology
through objective criteria. The derivation process of included
studies was rather weak, the two best ones fulfilling a maximum of
13 criteria over 20. The lack of weighting variables, of validation,
calibration and measures of reproducibility, the weak validities and
performances when assessed, and the absence of sensitivity
analyses all led to suboptimal quality and very debatable utility
of those clinical rules or prediction models for health practitioners
[40].
Other severity scores or indices are available in the literature
but since no data were available on their derivation process, they
were not included in this study: some of them were validated in
Fujitani [25] using the CDC definition of severity [6]. These
indices had moderate sensitivities, low predictive values, and poor
concordance with the CDC definition (0.18 to 0.69). Moreover,
included indices measured variables and risk factors at different
time points after CDI diagnosis [25].
Our systematic review has some limitations. As there were
relatively few prediction tools (only 13 identified), inclusion criteria
had to be permissive and we also examined publications with
limited information: four abstracts, a letter [28] and studies that
used only univariate analyses. Conference abstracts are not always
available online for reviewers.
Conclusion
In conclusion, available prediction tools for unfavourable
outcomes of CDI present many methodological biases and weak
validities, limiting their usefulness in clinical settings. Evidence-
based tools developed through appropriate prospective cohorts
would be more valuable for clinicians than empirically-selected
clinical factors.
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